JMP Securities analyst Silvan Tuerkcan has maintained their bullish stance on SLDB stock, giving a Buy rating on February 25.
Silvan Tuerkcan has given his Buy rating due to a combination of factors including Solid Biosciences’ recent positive developments in their Duchenne Muscular Dystrophy (DMD) program. The company reported strong initial data from their SGT-003 trial, showing consistent and robust expression in the first three patients, which has generated excitement and potential for the asset.
Additionally, the company has a solid financial position with a cash runway extending into the first half of 2027, following a successful fundraising. The anticipation of further clinical updates and potential regulatory discussions with the FDA in 2025, along with advanced CMC development metrics, further supports the positive outlook for Solid Biosciences. These factors combined suggest a promising trajectory for the company’s stock, justifying the Buy rating.
In another report released on February 25, Leerink Partners also maintained a Buy rating on the stock with a $20.00 price target.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SLDB in relation to earlier this year.